The Gibco ExpiCHO Expression System enables high-titer production of a broad range of recombinant proteins. Since the ExpiCHO kit components have been optimized for high-yield expression in CHO cells, some differences in supernatant clarification and protein purification are to be expected compared to existing transient expression systems utilizing HEK 293 cells (e.g., Gibco Expi293 Expression System). In some instances, vendor-recommended protein A purification protocols have been shown to be suboptimal for use with ExpiCHO supernatant, leading to a faint yellow discoloration of protein A columns over time. Here, an example of an optimized protocol for supernatant clarification and protein A purification is presented for the ExpiCHO Expression System.



Supernatant clarification

Note: For best results, clarification by centrifugation and filtration should be performed prior to freezing ExpiCHO supernatants.

Clarify ExpiCHO supernatants as follows:

  • Centrifuge supernatant at ≥3,000 x g for 30 minutes.
  • If using standard bottle-top vacuum filters, filtration of the supernatant using a 0.45 µm filter followed by a 0.22 µm filter is recommended (Cat. No. 166-0045 and 150-0020).
  • Other filters types (e.g., depth filters) may provide improved filtration compared to standard bottle-top vacuum filters.
  • For larger-volume filtration, one Pall Seltz PDK5 duallayered depth filter capsule with 0.0022 m2 surface area (Supracap™ 50 Depth Filter Capsules, Pall Cat. No. SC050PDK5) is recommended. For instance, 1 L of clarified supernatant can be processed at 8 mL/min with a processing time of 2 hr. The use of multiple capsules (e.g., two connected in parallel) will reduce processing times further. 

Column loading conditions

It is critical to load the optimal amount of monoclonal antibody (mAb) to achieve maximal purity and to maintain long-term consistency of resin performance. Because the ExpiCHO Expression System expresses many proteins at significantly higher levels than other expression systems, the amount of protein load per volume of resin should first be determined as follows:

  • Determine the antibody titer in the crude cell culture supernatant
  • Verify the dynamic binding capacity (DBC) of the resin at 5% breakthrough volume (C5)
  • Load 80% of the C5 of the resin 

Purification parameters

For all experimental conditions, the ÄKTA pure L chromatography system was used with linear velocity set to 150 cm/hr, and a residence time of 4 min. Protein A resin was equilibrated with 10 column volumes (CVs), and 28 mg of mAb per mL of resin was loaded. The column was then washed with 10 CVs of equilibration buffer, and elution was performed with 5 CVs of elution buffer. Finally, the column was re-equilibrated to return it to neutral conditions before sanitization for 10 min with 0.1 N sodium hydroxide. Before storage, the column was returned to neutral pH with equilibration buffer and then stored in 20% ethanol at 4°C.

Experimental design

Vendor-recommended (suboptimal) conditions for protein A purification are shown in Table 1. A custom design of experiment (DoE) model was made to determine factor significance and interactions during protein A purification of a human IgG1 (pI 8.68), with the end goal to maximize both monoclonal antibody recovery and impurity removal (Table 1).

Table 1. Comparison of test conditions for the vendor-recommended protocol and the test protocol for protein A purification.

Test conditionVendor-recommended protein A purification protocolDoE test condition ranges
Binding buffer typeSodium phosphateTris or sodium phosphate
Binding buffer concentration25 mM25–100 mM
Binding buffer pH7.47.1–7.4
Elution buffer typeCitrate, pH 3.0Citrate or acetate, pH 3.0
Elution buffer concentration100 mM25–100 mM
Addition of NaCl to binding or elution bufferBinding buffer onlyBinding or elution buffer
NaCl concentration150 mM15–150 mM



Individual DoE models were generated to obtain optimized conditions for both monoclonal antibody recovery and impurity removal. These two models were then merged to generate a final recommended purification protocol that maximized both recovery and impurity removal (Table 2). The data indicated that switching from the vendor-recommended condition of 25 mM sodium phosphate/150 mM NaCl for the binding buffer and 100 mM sodium citrate, pH 3.0 for the elution buffer, to the DoE-optimized conditions of 25 mM Tris/25 mM NaCl in the binding buffer and addition of at least 50–100 mM NaCl to the elution buffer (100 mM of either sodium citrate or sodium acetate, pH 3.0; Table 2), was sufficient to eliminate the impurity that led to the yellow discoloration of the protein A resin. Specifically, resolution of the impurity leading to the discoloration was achieved in the optimized condition (Figure 1 "Post-wash impurities"), whereas the distinct resolution of the impurity was not observed under the vendor-recommended condition (Figure 2).

Table 2. Optimized conditions for protein A purification of protein (mAb) generated using the ExpiCHO Expression System.

Test conditionOptimized factors
Binding buffer typeTris
Binding buffer concentration25 mM
Binding buffer pH7.1 or 7.4
Elution buffer typeAcetate or citrate, pH 3.0
Elution buffer concentration100 mM
Addition of NaCl to binding or elution bufferBinding or elution buffer
NaCl concentration25 mM for binding buffer and 50–100 mM for elution buffer
mAb purification using optimized conditions

Figure 1. Protein A resin elution profile of mAb expressed using ExpiCHO Expression System and purified using optimized conditions.

mAb purification using vendor-recommended conditions

Figure 2. Protein A resin elution profile of mAb expressed using ExpiCHO Expression System and purified using vendor-recommended conditions.


This application note provides recommendations on supernatant clarification, loading conditions, and buffers for protein A purification of ExpiCHO supernatants. The conditions determined in this study provided optimal product recovery and impurity removal. These conditions may be used as guidance for further optimization of purification conditions specific to particular proteins generated in the ExpiCHO Expression System.

For Research Use Only. Not for use in diagnostic procedures.